Page 1 | Search Results | Hematology, ASH Education Program

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy

Alison J. Moskowitz

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 207–212.

https://doi.org/10.1182/asheducation-2018.1.207

Published: 2018

Journal Articles

Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution

Nancy L. Bartlett

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 317–323.

https://doi.org/10.1182/asheducation-2017.1.317

Published: 2017

Journal Articles

Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma

Craig Moskowitz

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 331–338.

https://doi.org/10.1182/asheducation-2016.1.331

Published: 2016

Journal Articles

Second-line therapies in immune thrombocytopenia

Rachael F. Grace, Cindy Neunert

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 698–706.

https://doi.org/10.1182/asheducation-2016.1.698

Published: 2016

Journal Articles

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Holly L. Geyer, Ruben A. Mesa

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 277–286.

https://doi.org/10.1182/asheducation-2014.1.277

Published: 2014

Journal Articles

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?

Kendra Sweet, Vivian Oehler

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 184–188.

https://doi.org/10.1182/asheducation-2013.1.184

Published: 2013

Journal Articles

Novel therapeutic strategies: hypomethylating agents and beyond

Valeria Santini

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 65–73.

https://doi.org/10.1182/asheducation.V2012.1.65.3806843

Published: 2012

Journal Articles

Management of Essential Thrombocythemia

Francisco Cervantes

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 215–221.

https://doi.org/10.1182/asheducation-2011.1.215

Published: 2011

Journal Articles

Evidence-Based Mini-Review: Is Indium-Labeled Autologous Platelet Scanning Predictive of Response to Splenectomy in Patients With Chronic Immune Thrombocytopenia?

Adam Cuker, Douglas B. Cines

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 385–386.

https://doi.org/10.1182/asheducation-2010.1.385

Published: 2010

Journal Articles

Monitoring disease response to tyrosine kinase inhibitor therapy in CML

Timothy P. Hughes, Susan Branford

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 477–487.

https://doi.org/10.1182/asheducation-2009.1.477

Published: 2009

NARROW

Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy

Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution

Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma

Second-line therapies in immune thrombocytopenia

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?

Novel therapeutic strategies: hypomethylating agents and beyond

Management of Essential Thrombocythemia

Evidence-Based Mini-Review: Is Indium-Labeled Autologous Platelet Scanning Predictive of Response to Splenectomy in Patients With Chronic Immune Thrombocytopenia?

Monitoring disease response to tyrosine kinase inhibitor therapy in CML

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only